Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Return on Capital Employed (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Return on Capital Employed for 5 consecutive years, with 0.13% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Capital Employed rose 23.0% year-over-year to 0.13%, compared with a TTM value of 0.13% through Dec 2025, up 23.0%, and an annual FY2025 reading of 0.14%, up 25.0% over the prior year.
  • Return on Capital Employed was 0.13% for Q4 2025 at Kiniksa Pharmaceuticals International, up from 0.07% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.13% in Q4 2025 and bottomed at 0.79% in Q4 2021.
  • Average Return on Capital Employed over 5 years is 0.13%, with a median of 0.06% recorded in 2023.
  • The sharpest move saw Return on Capital Employed skyrocketed 81bps in 2022, then dropped -15bps in 2024.
  • Year by year, Return on Capital Employed stood at 0.79% in 2021, then soared by 103bps to 0.02% in 2022, then crashed by -341bps to 0.06% in 2023, then crashed by -71bps to 0.1% in 2024, then skyrocketed by 232bps to 0.13% in 2025.
  • Business Quant data shows Return on Capital Employed for KNSA at 0.13% in Q4 2025, 0.07% in Q3 2025, and 0.01% in Q2 2025.